Literature DB >> 16723576

Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus.

Lisa Friedman1, Jeff D Alder, Jared A Silverman.   

Abstract

Daptomycin is a lipopeptide antibiotic with potent activity against gram-positive bacteria. Complete-genome comparisons of laboratory-derived Staphylococcus aureus with decreased susceptibility to daptomycin and their susceptible parent were used to identify genes that contribute to reduced susceptibility to daptomycin. Selective pressure of growth in sublethal concentrations of daptomycin resulted in the accumulation of mutations over time correlating with incremental decreases in susceptibility. Single point mutations resulting in amino acid substitutions occurred in three distinct proteins: MprF, a lysylphosphatidylglycerol synthetase; YycG, a histidine kinase; and RpoB and RpoC, the beta and beta' subunits of RNA polymerase. Sequence analysis of mprF, yycF, yycG, rpoB, and rpoC in clinical isolates that showed treatment-emergent increases in daptomycin MICs revealed point mutations in mprF and a nucleotide insertion in yycG, suggesting a role for these genes in decreased susceptibility to daptomycin in the hospital setting.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16723576      PMCID: PMC1479123          DOI: 10.1128/AAC.00039-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  43 in total

1.  Role in cell permeability of an essential two-component system in Staphylococcus aureus.

Authors:  P K Martin; T Li; D Sun; D P Biek; M B Schmid
Journal:  J Bacteriol       Date:  1999-06       Impact factor: 3.490

2.  Mutations of bacterial RNA polymerase leading to resistance to microcin j25.

Authors:  Julia Yuzenkova; Monica Delgado; Sergei Nechaev; Dhruti Savalia; Vitaly Epshtein; Irina Artsimovitch; Rachel A Mooney; Robert Landick; Ricardo N Farias; Raul Salomon; Konstantin Severinov
Journal:  J Biol Chem       Date:  2002-10-24       Impact factor: 5.157

3.  Daptomycin in vitro activity tested against Gram-positive strains collected from European and Latin American medical centers in 2003.

Authors:  H S Sader; T R Fritsche; J M Streit; R N Jones
Journal:  J Chemother       Date:  2005-10       Impact factor: 1.714

4.  Mutation discovery in bacterial genomes: metronidazole resistance in Helicobacter pylori.

Authors:  Thomas J Albert; Daiva Dailidiene; Giedrius Dailide; Jason E Norton; Awdhesh Kalia; Todd A Richmond; Michael Molla; Jaz Singh; Roland D Green; Douglas E Berg
Journal:  Nat Methods       Date:  2005-11-18       Impact factor: 28.547

5.  Streptolydigin resistance can be conferred by alterations to either the beta or beta' subunits of Bacillus subtilis RNA polymerase.

Authors:  X Yang; C W Price
Journal:  J Biol Chem       Date:  1995-10-13       Impact factor: 5.157

6.  Biochemical characterization of the first essential two-component signal transduction system from Staphylococcus aureus and Streptococcus pneumoniae.

Authors:  Valerie A Clausen; Weonhye Bae; John Throup; Martin K R Burnham; Martin Rosenberg; Nicola G Wallis
Journal:  J Mol Microbiol Biotechnol       Date:  2003

7.  Complete genomes of two clinical Staphylococcus aureus strains: evidence for the rapid evolution of virulence and drug resistance.

Authors:  Matthew T G Holden; Edward J Feil; Jodi A Lindsay; Sharon J Peacock; Nicholas P J Day; Mark C Enright; Tim J Foster; Catrin E Moore; Laurence Hurst; Rebecca Atkin; Andrew Barron; Nathalie Bason; Stephen D Bentley; Carol Chillingworth; Tracey Chillingworth; Carol Churcher; Louise Clark; Craig Corton; Ann Cronin; Jon Doggett; Linda Dowd; Theresa Feltwell; Zahra Hance; Barbara Harris; Heidi Hauser; Simon Holroyd; Kay Jagels; Keith D James; Nicola Lennard; Alexandra Line; Rebecca Mayes; Sharon Moule; Karen Mungall; Douglas Ormond; Michael A Quail; Ester Rabbinowitsch; Kim Rutherford; Mandy Sanders; Sarah Sharp; Mark Simmonds; Kim Stevens; Sally Whitehead; Bart G Barrell; Brian G Spratt; Julian Parkhill
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-22       Impact factor: 11.205

8.  Genes controlled by the essential YycG/YycF two-component system of Bacillus subtilis revealed through a novel hybrid regulator approach.

Authors:  Alistair Howell; Sarah Dubrac; Kasper Krogh Andersen; David Noone; Juliette Fert; Tarek Msadek; Kevin Devine
Journal:  Mol Microbiol       Date:  2003-09       Impact factor: 3.501

Review 9.  Insights on antibiotic resistance of Staphylococcus aureus from its whole genome: genomic island SCC.

Authors:  Teruyo Ito; Keiko Okuma; Xiao Xue Ma; Harumi Yuzawa; Keiichi Hiramatsu
Journal:  Drug Resist Updat       Date:  2003-02       Impact factor: 18.500

10.  Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus.

Authors:  L Ferrero; B Cameron; J Crouzet
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

View more
  203 in total

1.  Daptomycin-mediated reorganization of membrane architecture causes mislocalization of essential cell division proteins.

Authors:  Joe Pogliano; Nicolas Pogliano; Jared A Silverman
Journal:  J Bacteriol       Date:  2012-06-01       Impact factor: 3.490

2.  Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.

Authors:  Molly E Steed; Celine Vidaillac; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

Review 3.  Roles of tRNA in cell wall biosynthesis.

Authors:  Kiley Dare; Michael Ibba
Journal:  Wiley Interdiscip Rev RNA       Date:  2012-01-19       Impact factor: 9.957

4.  Regulation of mprF by antisense RNA restores daptomycin susceptibility to daptomycin-resistant isolates of Staphylococcus aureus.

Authors:  Aileen Rubio; Mary Conrad; Robert J Haselbeck; Kedar G C; Vickie Brown-Driver; John Finn; Jared A Silverman
Journal:  Antimicrob Agents Chemother       Date:  2010-10-25       Impact factor: 5.191

5.  Development of daptomycin nonsusceptibility with heterogeneous vancomycin-intermediate resistance and oxacillin susceptibility in methicillin-resistant Staphylococcus aureus during high-dose daptomycin treatment.

Authors:  Chen-Hsiang Lee; Ming-Chung Wang; I-Wen Huang; Feng-Jui Chen; Tsai-Ling Lauderdale
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

6.  Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.

Authors:  H F Chambers; L Basuino; B A Diep; J Steenbergen; S Zhang; P Tattevin; J Alder
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

7.  Characterisation of a Staphylococcus aureus strain with progressive loss of susceptibility to vancomycin and daptomycin during therapy.

Authors:  Fred C Tenover; Scott W Sinner; Robert E Segal; Vanthida Huang; Shandline S Alexandre; John E McGowan; Melvin P Weinstein
Journal:  Int J Antimicrob Agents       Date:  2009-02-23       Impact factor: 5.283

8.  daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Authors:  Warren E Rose; Steven N Leonard; George Sakoulas; Glenn W Kaatz; Marcus J Zervos; Anjly Sheth; Christopher F Carpenter; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2007-11-12       Impact factor: 5.191

9.  In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.

Authors:  Amira A Bhalodi; Mao Hagihara; David P Nicolau; Joseph L Kuti
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

Review 10.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.